What is Avinger?
Avinger designs, manufactures, and sells image-guided and catheter-based systems aimed at treating patients with peripheral artery disease (PAD). The company's core innovation lies in its lumivascular platform, which integrates optical coherence tomography (OCT) visualization with interventional catheters. This technology provides real-time intravascular imaging during PAD procedures, enabling physicians to more precisely diagnose and treat arterial blockages. Key products include the Lightbox imaging consoles, Ocelot and Tigereye devices for penetrating total blockages, and the Pantheris image-guided atherectomy device for plaque removal. Avinger also has the IMAGE-BTK product in development for below-the-knee PAD lesions. The company markets its solutions to interventional cardiologists, vascular surgeons, and interventional radiologists, primarily in the United States and Germany.
How much funding has Avinger raised?
Avinger has raised a total of $125M across 6 funding rounds:
Debt
$10.5M
Stock Offering
$65M
Debt
$33M
Debt
$10M
Stock Offering
$4.5M
Debt
$2M
Debt (2013): $10.5M, investors not publicly disclosed
Stock Issuance/Offering (2015): $65M, investors not publicly disclosed
Debt (2015): $33M supported by CRG
Debt (2016): $10M featuring CRG LP
Stock Issuance/Offering (2019): $4.5M, investors not publicly disclosed
Debt (2020): $2M with participation from PPP
Key Investors in Avinger
CRG LP
CRG LP is a global investment firm specializing in credit and select equity investments across the healthcare sector, providing flexible growth capital solutions. Their focus on life sciences and healthcare services makes them a strategic partner for companies like Avinger.
CRG
CRG is a prominent investment entity with a significant track record in financing healthcare innovations. Their involvement suggests a belief in Avinger's technology and market potential within the medical device industry.
What's next for Avinger?
With the recent influx of major strategic investment and a history of significant capital raises, Avinger is positioned for accelerated growth and product development. The company's focus on advancing its lumivascular platform and expanding its product pipeline, particularly for challenging below-the-knee PAD lesions, indicates a strategic push to capture a larger share of the cardiovascular intervention market. Future endeavors will likely involve scaling manufacturing, expanding commercial reach, and potentially pursuing further strategic partnerships or financing rounds to support ongoing innovation and market adoption of its image-guided medical devices. The company's trajectory suggests a commitment to enhancing physician capabilities in treating complex PAD cases.
See full Avinger company page
